CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease

Gaucher disease (GD) is caused by a deficiency of glucocerebrosidase and the consequent lysosomal accumulation of unmetabolized glycolipid substrates. Enzyme-replacement therapy adequately manages the visceral manifestations of nonneuronopathic type-1 Gaucher patients, but not the brain disease in n...

Descripción completa

Detalles Bibliográficos
Autores principales: Marshall, John, Sun, Ying, Bangari, Dinesh S, Budman, Eva, Park, Hyejung, Nietupski, Jennifer B, Allaire, Amy, Cromwell, Mary A, Wang, Bing, Grabowski, Gregory A, Leonard, John P, Cheng, Seng H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923322/
https://www.ncbi.nlm.nih.gov/pubmed/26948439
http://dx.doi.org/10.1038/mt.2016.53

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923322/
https://www.ncbi.nlm.nih.gov/pubmed/26948439
http://dx.doi.org/10.1038/mt.2016.53

Ejemplares similares